Newly approved PI provides treatment options
- PMID: 11364360
Newly approved PI provides treatment options
Abstract
AIDS: The Food and Drug Administration (FDA) recently approved nelfinavir (Viracept), the fourth protease inhibitor on the market. It is unclear where it fits in the treatment arsenal, although it appears to have fewer severe side effects than the other three protease inhibitors already being prescribed. One potential drawback to using the drug is that early data suggest that resistance to nelfinavir can cause cross-resistance to the other drugs.
Similar articles
-
Nelfinavir - major trial results at retroviruses conference.AIDS Treat News. 1997 Feb 21;(No 265):3-4. AIDS Treat News. 1997. PMID: 11364240
-
Nelfinavir (Viracept).BETA. 1997 Mar:5. BETA. 1997. PMID: 11364528
-
Nelfinavir at six months.PI Perspect. 1997 Mar;(No 21):11-2. PI Perspect. 1997. PMID: 11364207
-
Nelfinavir, a new protease inhibitor: early clinical results.AIDS. 1999 Sep;13 Suppl 1:S41-8. AIDS. 1999. PMID: 10546784 Review.
-
Nelfinavir.Drugs. 1997 Jul;54(1):81-7; discussion 88. doi: 10.2165/00003495-199754010-00007. Drugs. 1997. PMID: 9211082 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous